|
 
- 现金
- 20620 元
- 精华
- 7
- 帖子
- 12759
- 注册时间
- 2013-12-29
- 最后登录
- 2024-6-18
|
本帖最后由 newchinabok 于 2015-6-19 13:11 编辑
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Resource links provided by NLM:
MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis B
U.S. FDA Resources
Further study details as provided by Arrowhead Research Corporation:
Primary Outcome Measures:
Depth and duration of HBsAg reduction as a measure of efficacy [ Time Frame: Through Day 85 ] [ Designated as safety issue: No
Estimated Enrollment: 16 (估计 16人）
Study Start Date: March 2014
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure |
|
楼主: StephenW
发表于 2015-6-19 12:54
